Key facts
- Notable investors include Shanghai Guofang Private Equity Fund Management Company, Northern Territory Incubator, Dingxin Capital, Xingkong Capital, Yield Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Sinuo New Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Sinuo New Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sinuo New Medicine
Developer of innovative radiopharmaceuticals designed to improve outcomes for cancer patients. The company offers the development of targeting radioisotope-labeled drugs, thereby permitting the establishment of an innovative radiopharmaceutical R&D platform with core drug R&D technologies and advanced development strategies.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Sinuo New Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sinuo New Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sinuo New Medicine in its N-PORT filings yet. We sweep new filings monthly.